SEC Filings TLDR Banner

Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.

Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.

Filter by Form Type:
All346-K8-K10-Q144Schedule 13GSchedule 13G/ASchedule 13DSchedule 13D/A
Industry:Biotechnologyβœ•
Previous Page89101112131415Next Page
2026-05-15CBIOSCHEDULE 13GBalyasny Asset Management Acquires 5.48% Stake in Crescent Biopharma, Inc. (CBIO)MEDIUM
Balyasny Asset Management L.P. (BAM) filed a Schedule 13G on May 15, 2026, disclosing a new 5.48% stake in Crescent Biopharma, Inc. (CBIO). The filing indicates that the reporting persons collectively beneficially own 1,510,033 shares of common stock as of the event date on March 31, 2026. This position is held through...
Small CapBiotechnologyownership +5.48%
2026-05-15CYBNSCHEDULE 13GSirenia Capital Management LP Reports New 7.2% Stake in Cybin Inc. (CYBN)MEDIUM
On May 15, 2026, Sirenia Capital Management LP and Alex Silverstein filed a Schedule 13G with the SEC, reporting a 7.2% stake in Cybin Inc. (ticker: CYBN). The reporting persons beneficially own 3,677,966 common shares, which includes 969,500 shares issuable upon the exercise of warrants held by the SILV Fund, Ltd., an...
Biotechnologyownership +7.20%
2026-05-15CLDISCHEDULE 13GArmistice Capital, LLC Reports New 9.99% Passive Stake in Calidi Biotherapeutics (CLDI)HIGH
On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G disclosing a new 9.99% stake in Calidi Biotherapeutics, Inc. (CLDI). The reporting persons reported beneficial ownership of 1,111,732 shares of common stock as of the event date of March 31, 2026. Armistice Capital, LLC s...
Nano CapBiotechnologyownership +9.99%
2026-05-15CAMPSCHEDULE 13GBalyasny Asset Management Reports New 5.07% Stake in Camp4 Therapeutics Corp.MEDIUM
On May 15, 2026, Balyasny Asset Management L.P. (BAM) filed a Schedule 13G indicating a new 5.07% ownership stake in Camp4 Therapeutics Corp. (CAMP). The reporting persons, which include BAM, BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, reported beneficial ownership of 2,632,437...
Micro CapBiotechnologyownership +5.07%
2026-05-15CADLSCHEDULE 13GRTW Investments and Roderick Wong Acquire 8.8% Stake in Candel Therapeutics (CADL)HIGH
On May 15, 2026, RTW Investments, LP and Roderick Wong, M.D. filed a Schedule 13G with the SEC, disclosing a new 8.8% ownership stake in Candel Therapeutics, Inc. (CADL). The reporting persons beneficially own 6,422,018 shares of common stock as of the event date on March 31, 2026. RTW Investments, LP, a Delaware limit...
Small CapBiotechnologyownership +8.80%
2026-05-15CELCSCHEDULE 13GRTW Investments, LP Reports New 6.3% Stake in Celcuity Inc. (CELC)MEDIUM
On May 15, 2026, RTW Investments, LP and Roderick Wong, M.D. filed a Schedule 13G disclosing a new 6.3% ownership stake in Celcuity Inc. (CELC). The reporting persons beneficially own 3,039,621 shares of common stock as of the event date of March 31, 2026. RTW Investments, a Delaware limited partnership, serves as the ...
Mid CapBiotechnologyownership +6.30%
2026-05-15CNTASCHEDULE 13GPentwater Capital Management LP Reports New 5.3% Stake in Centessa Pharmaceuticals plcMEDIUM
On May 15, 2026, Pentwater Capital Management LP and its principal, Matthew Halbower, filed a Schedule 13G disclosing a new 5.3% ownership stake in Centessa Pharmaceuticals plc (CNTA). The Reporting Persons beneficially own 8,170,000 ordinary shares, which are held in the form of American Depositary Shares (ADSs). Each...
Mid CapBiotechnologyownership +5.30%
Sponsored
2026-05-15IPSCSCHEDULE 13GRTW Investments, LP Acquires 7.1% Stake in Century Therapeutics, Inc. (IPSC)HIGH
RTW Investments, LP, and its Managing Partner, Roderick Wong, M.D., have filed a Schedule 13G indicating a new 7.1% stake in Century Therapeutics, Inc. (IPSC) as of March 31, 2026. The reporting persons beneficially own 13,043,478 shares of common stock. This total includes 4,347,826 shares issuable upon the exercise o...
Small CapBiotechnologyownership +7.10%
Previous Page89101112131415Next Page